Hypertrophic cardiomyopathy in children

Heart

Volumn 98, Issue 14, 2012, Pages 1044-1054

  Moak, Jeffrey P ^a   Kaski, Juan Pablo ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE; DIURETIC AGENT; MEMBRANE PROTEIN; METOPROLOL; PROPRANOLOL; SARCOMERE PROTEIN; UNCLASSIFIED DRUG; VERAPAMIL;

ARTIFICIAL HEART PACEMAKER; CHILD; CHILD HEALTH CARE; CHILDHOOD MORTALITY; CONGESTIVE HEART FAILURE; DEFIBRILLATION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; ECG ABNORMALITY; ECHOCARDIOGRAPHY; FAMILY HISTORY; FATTY ACID METABOLISM; GENE; GENE MUTATION; GENETIC COUNSELING; GLYCOGEN STORAGE DISEASE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MURMUR; HEART MUSCLE ISCHEMIA; HEART SURGERY; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INBORN ERROR OF METABOLISM; INHERITANCE; KEARNS SAYRE SYNDROME; MALFORMATION SYNDROME; MELAS SYNDROME; MERRF SYNDROME; NEUROMUSCULAR DISEASE; PATIENT REFERRAL; PRIORITY JOURNAL; PROTECTION; RADIOFREQUENCY ABLATION; REVIEW; RISK ASSESSMENT; SARCOMERE PROTEIN GENE; SPORT; SUDDEN DEATH; SURVIVAL RATE;

CARDIOMYOPATHY, HYPERTROPHIC; CHILD; DEATH, SUDDEN, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MORBIDITY; SURVIVAL RATE; WORLD HEALTH;

EID: 84862898942     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300531     Document Type: Review

References (103)

1. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003;348:1647-55. (Pubitemid 36459470)
2. Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003;348:1639-46. (Pubitemid 36459469)
3. Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009;119:1085-92.
4. Biagini E, Coccolo F, Ferlito M, et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005;46:1543-50. (Pubitemid 41446193)
5. Rodriguez JE, McCudden CR, Willis MS. Familial hypertrophic cardiomyopathy: basic concepts and future molecular diagnostics. Clin Biochem 2009;42:755-65.
6. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008;29:270-6.
7. Hada Y, Sakamoto T, Amano K, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol 1987;59:183-4. (Pubitemid 17077102)
8. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:785-9.
9. Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006;113:2697-705. (Pubitemid 43947987)
10. Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 2004;116:14-18. (Pubitemid 38050021)
11. Arola A, Jokinen E, Ruuskanen O, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. Am J Epidemiol 1997;146:385-93. (Pubitemid 27377515)
12. Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007;115:773-81. (Pubitemid 46294745)
13. Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alphaglucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24-31. (Pubitemid 41556629)
14. Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 2009;11:210-19.
15. Sugie K, Yamamoto A, Murayama K, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002;58:1773-8. (Pubitemid 34663577)
16. Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001;10:1215-20. (Pubitemid 32487544)
17. Murphy RT, Mogensen J, McGarry K, et al. Adenosine monophosphate- activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson- White syndrome: natural history. J Am Coll Cardiol 2005;45:922-30. (Pubitemid 40342820)
18. Kelly BP, Russell MW, Hennessy JR, et al. Severe hypertrophic cardiomyopathy in an infant with a novel PRKAG2 gene mutation: potential differences between infantile and adult onset presentation. Pediatr Cardiol 2009;30:1176-9.
19. Brown-Harrison MC, Nada MA, Sprecher H, et al. Very long chain acyl-CoA dehydrogenase deficiency: successful treatment of acute cardiomyopathy. Biochem Mol Med 1996;58:59-65. (Pubitemid 26230530)
20. Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res 2005;57:78R-86R. (Pubitemid 40593250)
21. Scaglia F, Towbin JA, Craigen WJ, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 2004;114:925-31. (Pubitemid 41529754)
22. Holmgren D, Wahlander H, Eriksson BO, et al. Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J 2003;24:280-8. (Pubitemid 36207084)
23. Limongelli G, Tome-Esteban M, Dejthevaporn C, et al. Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease. Eur J Heart Fail 2010;12:114-21.
24. Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RASMAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci 2010;1214:99-121.
25. Sharland M, Burch M, McKenna WM, et al. A clinical study of Noonan syndrome. Arch Dis Child 1992;67:178-83.
26. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol 2010;1:2-26.
27. Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2010;126:746-59.
28. Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 2002;87:346-9. (Pubitemid 34270947)
29. Kearney M, Orrell RW, Fahey M, et al. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev 2009;(4):CD007791.
30. Drinkard BE, Keyser RE, Paul SM, et al. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch Phys Med Rehabil 2010;91:1044-50.
31. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001;33:655-70. (Pubitemid 32538979)
32. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227-32. (Pubitemid 36547217)
33. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 2005;6:185-216. (Pubitemid 41397081)
34. Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation 2010;122:2441-9; discussion 2450.
35. Maron BJ. Hypertrophic cardiomyopathy in childhood. Pediatr Clin North Am 2004;51:1305-46. (Pubitemid 39157342)
36. Maron BJ, Spirito P, Wesley Y, et al. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986;315:610-14. (Pubitemid 16046974)
37. Kaski JP, Syrris P, Esteban MT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2009;2:436-41.
38. Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008;358:1899-908. (Pubitemid 351620110)
39. Hayati AR, Cheah FC, Tan AE, et al. Insulin-like growth factor-1 receptor expression in the placentae of diabetic and normal pregnancies. Early Hum Dev 2007;83:41-6. (Pubitemid 46038643)
40. Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 1982;65:7-17. (Pubitemid 12250883)
41. Ostman-Smith I, Wettrell G, Keeton B, et al. Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur Heart J 2008;29:1160-7. (Pubitemid 351844886)
42. Lakdawala NK, Thune JJ, Maron BJ, et al. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol 2011;108:1606-13.
43. Nugent AW, Daubeney PE, Chondros P, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 2005;112:1332-8. (Pubitemid 41266729)
44. Ho CY, Carlsen C, Thune JJ, et al. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2009;2:314-21.
45. McMahon CJ, Nagueh SF, Pignatelli RH, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004;109:1756-62. (Pubitemid 38528696)
46. Menon SC, Ackerman MJ, Cetta F, et al. Significance of left atrial volume in patients < 20 years of age with hypertrophic cardiomyopathy. Am J Cardiol 2008;102:1390-3.
47. McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532-8. (Pubitemid 11137648)
48. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child 1984;59:971-5. (Pubitemid 14018125)
49. Yetman AT, Hamilton RM, Benson LN, et al. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998;32:1943-50. (Pubitemid 29010459)
50. Cox GF. Diagnostic approaches to pediatric cardiomyopathy of metabolic genetic etiologies and their relation to therapy. Prog Pediatr Cardiol 2007;24:15-25. (Pubitemid 47576679)
51. Berger S, Dhala A, Dearani JA. State-of-the-art management of hypertrophic cardiomyopathy in children. Cardiol Young 2009;19(Suppl 2):66-73.
52. Decker JA, Rossano JW, Smith EO, et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol 2009;54:250-4.
53. Ostman-Smith I, Wettrell G, Keeton B, et al. Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly. Cardiol Young 2005;15:632-42. (Pubitemid 41748558)
54. Moran AM, Colan SD. Verapamil therapy in infants with hypertrophic cardiomyopathy. Cardiol Young 1998;8:310-19. (Pubitemid 128681693)
55. Skinner JR, Manzoor A, Hayes AM, et al. A regional study of presentation and outcome of hypertrophic cardiomyopathy in infants. Heart 1997;77:229-33. (Pubitemid 27122773)
56. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-41. (Pubitemid 44297366)
57. Peteiro J, Bouzas-Mosquera A, Fernandez X, et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2012;25:182-9.
58. Haberer T, Hess OM, Jenni R, et al. [Hypertrophic obstructive cardiomyopathy: spontaneous course in comparison to long-term therapy with propranolol and verapamil] (In German). Z Kardiol 1983;72:487-93.
59. Duncan WJ, Tyrrell MJ, Bharadwaj BB. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children. Can J Cardiol 1991;7:81-6.
60. Ostman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. Fundam Clin Pharmacol 2010;24:637-52.
61. Teraguchi M, Ikemoto Y, Kobayashi Y. Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy. Circ J 2002;66:709-11. (Pubitemid 34733537)
62. Spicer RL, Rocchini AP, Crowley DC, et al. Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy. Am J Cardiol 1984;53:1614-19. (Pubitemid 14112319)
63. Dearani JA, Ommen SR, Gersh BJ, et al. Surgery insight: septal myectomy for obstructive hypertrophic cardiomyopathyethe Mayo Clinic experience. Nat Clin Pract Cardiovasc Med 2007;4:503-12. (Pubitemid 47321549)
64. Minakata K, Dearani JA, O'Leary PW, et al. Septal myectomy for obstructive hypertrophic cardiomyopathy in pediatric patients: early and late results. Ann Thorac Surg 2005;80:1424-9; discussion 1429-30.
65. Ommen SR, Maron BJ, Olivotto I, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470-6. (Pubitemid 41040288)
66. Seiler C, Hess OM, Schoenbeck M, et al. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol 1991;17:634-42.
67. Fananapazir L, Epstein ND, Curiel RV, et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994;90:2731-42.
68. Rishi F, Hulse JE, Auld DO, et al. Effects of dual-chamber pacing for pediatric patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1997;29:734-40. (Pubitemid 27128244)
69. Lenarczyk R, Kowalski O, Kukulski T, et al. Resynchronization or dyssynchronizationdsuccessful treatment with biventricular stimulation of a child with obstructive hypertrophic cardiomyopathy without dyssynchrony. J Cardiovasc Electrophysiol 2007;18:542-4. (Pubitemid 46650331)
70. Czosek RJ, Meganathan K, Anderson JB, et al. Cardiac rhythm devices in the pediatric population: Utilization and complications. Heart Rhythm 2012;9:199-208.
71. Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardiol 2006;19:319-27. (Pubitemid 44185823)
72. Cano MN, Fortunato de Cano SJ, Sousa JE. Alcohol septal ablation after myomectomy failure solutions for unusual cases. Catheter Cardiovasc Interv 2010;76:719-23.
73. Singh H, Kalra R, Keshavamurthy GB, et al. Percutaneous transluminal septal myocardial ablation in a child with hypertrophic obstructive cardiomyopathy and Noonan syndrome. Congenit Heart Dis 2008;3:347-51.
74. Emmel M, Sreeram N, deGiovanni JV, et al. Radiofrequency catheter septal ablation for hypertrophic obstructive cardiomyopathy in childhood. Z Kardiol 2005;94:699-703. (Pubitemid 41414427)
75. Sreeram N, Emmel M, de Giovanni JV. Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children. J Am Coll Cardiol 2011;58:2501-10.
76. Olivotto I, Cecchi F, Bini R, et al. Tunneled left anterior descending artery in a child with hypertrophic cardiomyopathy. Nat Clin Pract Cardiovasc Med 2009;6:134-9.
77. Mohiddin SA, Begley D, Shih J, et al. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. J Am Coll Cardiol 2000;36:2270-8.
78. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596-601.
79. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-18.
80. Moak JP, Leifer ES, Tripodi D, et al. Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events. Pediatr Cardiol 2011;32:1096-105.
81. McKenna WJ, Franklin RC, Nihoyannopoulos P, et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:147-53. (Pubitemid 18029049)
82. Olivotto I, Gistri R, Petrone P, et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;41:315-21. (Pubitemid 36092203)
83. Yetman AT, McCrindle BW, MacDonald C, et al. Myocardial bridging in children with hypertrophic cardiomyopathyda risk factor for sudden death. N Engl J Med 1998;339:1201-9. (Pubitemid 28482129)
84. Limongelli G, Miele T, Pacileo G, et al. Heart rate variability is a weak predictor of sudden death in children and young patients with hypertrophic cardiomyopathy. Heart 2007;93:117-18. (Pubitemid 46094071)
85. Maskatia SA, Decker JA, Spinner JA, et al. Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy. Pediatr Cardiol 2012;33:141-9.
86. Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 2007;93:708-10. (Pubitemid 46808272)
87. Frank MJ, Abdulla AM, Canedo MI, et al. Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol 1978;42:993-1001.
88. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/ European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-91. (Pubitemid 37336422)
89. Corrado D, Pelliccia A, Bjornstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005;26:516-24. (Pubitemid 40326204)
90. Pelliccia A, Di Paolo FM, Corrado D, et al. Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. Eur Heart J 2006;27:2196-200. (Pubitemid 44418944)
91. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverterdefibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73. (Pubitemid 30084534)
92. Kaski JP, Tome Esteban MT, Lowe M, et al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart 2007;93:372-4. (Pubitemid 46579536)
93. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 2008;51:1685-91. (Pubitemid 351626414)
94. Celiker A, Olgun H, Karagoz T, et al. Midterm experience with implantable cardioverter-defibrillators in children and young adults. Europace 2010;12:1732-8.
95. Heersche JH, Blom NA, van de Heuvel F, et al. Implantable cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands. Pacing Clin Electrophysiol 2010;33:179-85.
96. Von Bergen NH, Atkins DL, Dick M 2nd, et al. Multicenter study of the effectiveness of implantable cardioverter defibrillators in children and young adults with heart disease. Pediatr Cardiol 2011;32:399-405.
97. Lin G, Nishimura RA, Gersh BJ, et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 2009;95:709-14.
98. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006;114:216-25. (Pubitemid 44297115)
99. Beder SD, Gutgesell HP, Mullins CE, et al. Progression from hypertrophic obstructive cardiomyopathy to congestive cardiomyopathy in a child. Am Heart J 1982;104:155-6. (Pubitemid 13114597)
100. Ino T, Nishimoto K, Okubo M, et al. Apoptosis as a possible cause of wall thinning in end-stage hypertrophic cardiomyopathy. Am J Cardiol 1997;79:1137-41. (Pubitemid 27217078)
101. Gajarski R, Naftel DC, Pahl E, et al. Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant. J Heart Lung Transplant 2009;28:1329-34.
102. Maron MS, Kalsmith BM, Udelson JE, et al. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010;3:574-9.
103. Charron P, Arad M, Arbustini E, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2010;31:2715-26.